Molnupiravir, a Covid antiviral drug, was launched in India on Monday for Rs 1,399 for a five-day course for mild to moderate infection.

An expert panel of the Central Drugs Standard Control Organisation recently approved the antiviral drug Molnupiravir for restricted use in an emergency situation, amidst a surge in Omicron cases in the country.

The CDSCO has also given emergency use authorization to the Serum Institute of India’s Covid vaccine COVOVAX, Hyderabad-based Biological E RBD Protein CORBEVAX, in addition to Molnupiravir.

Molnupiravir is an antiviral drug that prevents certain RNA viruses from replicating. It’s used to treat COVID-19 in people who have been infected with the SARS-CoV-2 virus. Molnupiravir 800 mg twice a day for five days is the recommended dose.

A patient must take 40 capsules with a total dose of 200 mg of medication. The oral pill is being developed by a number of pharmaceutical companies, including Torrent, Cipla, Sun Pharma, Dr. Reddy’s, Natco, Mylan, and Hetero.

Molnupiravir capsules are also expected to be released in the coming weeks by Cipla, Sun Pharma, and Dr. Reddy’s Laboratories.

This Covid antiviral pill, a joint venture between MSD and Ridgeback Biotherapeutics, is the first anti-Covid pill to be approved by the UK’s drug regulator.

The pill has also been approved by the US Food and Drug Administration (USFDA) for the treatment of mild-to-moderate Covid-19 in adults, as well as those who are at a high risk of developing severe disease.

Cipla intends to market Molnupiravir under the Cipmolnu brand name. Cipmolnu 200mg capsules will be available in leading pharmacies and Covid treatment centres across the country in the near future. Dr. Reddy’s said it would soon launch Molnupiravir 200mg capsules in the country under the brand name Molflu.

For more Latest News Updates visit our website- https://www.eastnews.in/

For Arunachal Latest News updates Visit- https://www.eastnews.in/arunachal-pradesh-news/